Literature DB >> 12505426

Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain.

Troy T Rohn1, Robert A Rissman, Michael C Davis, Young Eun Kim, Carl W Cotman, Elizabeth Head.   

Abstract

Accumulating evidence supports a role for the activation of proteolytic enzymes, caspases, in the Alzheimer's disease (AD) brain. Neurons committed to apoptosis may do so through a mitochondrial pathway employing caspase-9 or through an alternative, receptor-mediated pathway involving caspase-8. Considering the role of mitochondrial dysfunction in AD, we examined the possible activation of caspase-9 in the AD brain using an antibody that recognizes the active fragments of caspase-9, but not the full-length proform of the enzyme. In vivo immunohistochemical analysis demonstrated little caspase-9 activation in the majority of hippocampal brain sections from control brains. However, labeling of neurons as well as dystrophic neurites within plaque regions was observed in all AD hippocampal brain sections examined. In addition, active caspase-9 was colocalized with active caspase-8 and the accumulation of caspase-3-cleavage products of fodrin. The activation of caspase-9 was also observed in neurons positive for oxidative damage to DNA/RNA. A quantitative analysis indicates that as the number of neurons containing neurofibrillary tangles (NFTs) increases, the extent of caspase-9 activation decreases, supporting the idea that caspase-9 activation may precede NFT formation. In addition, a site-directed caspase-cleavage antibody was designed to the amino-terminal caspase-3 consensus cleavage site located in tau, and shown to be an effective marker for caspase-cleaved fragments of tau in vitro. Analysis with this antibody using age-matched control or AD brain sections demonstrated no staining in control brains while widespread labeling of NFTs, neuropil threads, and dystrophic neurites was observed in AD sections. Taken together, these results demonstrate the activation of caspases and cleavage of tau in the AD brain, events which may precede and lead to the formation of NFTs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12505426     DOI: 10.1006/nbdi.2002.0549

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  92 in total

Review 1.  Caspase-mediated degeneration in Alzheimer's disease.

Authors:  David H Cribbs; Wayne W Poon; Robert A Rissman; Mathew Blurton-Jones
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

2.  Calcium induces expression of cytoplasmic gelsolin in SH-SY5Y and HEK-293 cells.

Authors:  Lina Ji; Abha Chauhan; Ved Chauhan
Journal:  Neurochem Res       Date:  2010-03-26       Impact factor: 3.996

3.  Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease.

Authors:  Siddhartha Mondragón-Rodríguez; Gustavo Basurto-Islas; Ismael Santa-Maria; Raúl Mena; Lester I Binder; Jesús Avila; Mark A Smith; George Perry; Francisco García-Sierra
Journal:  Int J Exp Pathol       Date:  2008-04       Impact factor: 1.925

4.  CASP3 and LDOC-1 gene expression in a patient with carcinoma in the hairy part of the head skin and Alzheimer disease.

Authors:  Michele Salemi; Pier Franco Soma; Paolo Bosco; Enzo Vicari; Roberto Castiglione; Castiglione Roberto; Aldo E Calogero
Journal:  Hum Cell       Date:  2013-06-18       Impact factor: 4.174

Review 5.  Cell death in brain development and degeneration: control of caspase expression may be key!

Authors:  Shane D Madden; Thomas G Cotter
Journal:  Mol Neurobiol       Date:  2008-05-01       Impact factor: 5.590

6.  Caspases as therapeutic targets in Alzheimer's disease: is it time to "cut" to the chase?

Authors:  Troy T Rohn; Elizabeth Head
Journal:  Int J Clin Exp Pathol       Date:  2008-06-10

7.  Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease.

Authors:  Natalia Louneva; Julia W Cohen; Li-Ying Han; Konrad Talbot; Robert S Wilson; David A Bennett; John Q Trojanowski; Steven E Arnold
Journal:  Am J Pathol       Date:  2008-09-25       Impact factor: 4.307

Review 8.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012

9.  Apoptosis and in vitro Alzheimer disease neuronal models.

Authors:  P Calissano; C Matrone; G Amadoro
Journal:  Commun Integr Biol       Date:  2009

10.  Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh.

Authors:  Troy T Rohn; Polina Kokoulina; Cody R Eaton; Wayne W Poon
Journal:  Int J Clin Exp Med       Date:  2009-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.